Scilex price to sales ratio SCLX

Market value divided by revenue over the last twelve months, since 2023.

Today, Oct 23, 2026: 0.6×
3-year median: 2.3×
Against its 3-year history: 3rd; percentile: 0 is its lowest day, 100 its highest
3-year range: 0.5× to 7.5×
Peer median: 1.4×

Scilex's price to sales ratio is 0.6× as of Oct 23, 2026.

That is below its 3-year median of 2.3×, lower than on 97% of days in the last 3 years.

Over that time it ranged from 0.5× in May 2025 to 7.5× in Jul 2024.

The median for 8 healthcare stocks of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.6×	0.6×	3.0×
2025	2.6×	0.5×	4.6×
2024	1.5×	1.5×	7.5×
2023	7.0×	3.7×	7.0×

Against its peers

Companies in Healthcare nearest Scilex's size, closest first, today.

Company	Price to sales ratio
SCLXScilex	0.6×
NEPHNephros	1.9×
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	0.9×
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
ICCCImmucell	3.0×
KEQUKewaunee Scientific	0.3×
PDEXPro DEX	2.6×
Peer median	1.4×

Where Scilex ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Scilex

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.